New products necessitating blood transfusions 3- “Paclitaxel” Prescr Intern 1994; 3 (14): 164-165. Literature 4- Rowisky EK et al. “Phase I and pharmacolog- occurred in 37% of patients (9). ic study of topotecan: a novel topoisomerase I The most frequent non haematologi- Our literature search was based on systematic inhibitor” J Clin Oncol 1992; 10: 647-656. cal side effects were nausea (68.1% of scrutiny of contents listings of the main inter- 5- Verweij L et al. “Phase I and pharmacokinet- ics study of topotecan, a new topoisomerase I patients, severe in 6.1% of patients), national journals and Current Contents at inhibitor” Ann Oncol 1993; 4: 673-678. vomiting (44.3%, severe in 4.5%), hair the Prescrire library, and on reference texts 6- Saltz L et al. “Phase I clinical and pharmacol- in clinical pharmacology (Martindale The ogy study of topotecan given daily for 5 consecu- loss (56.9%), fatigue (44.5%, severe in Extra Pharmacopoeia 31st ed., etc.). We also tive days to patients with advanced solid tumors, 6%), diarrhoea (26.1%, severe in 3.4%), consulted CD-ROM versions of Medline (1981- with attempt at dose intensification using recom- and stomatitis (20.2%, severe in 2%) (9). March 1998), Embase Drugs and binant granulocyte colony-stimulating factor” J Pharmacology (1991-January 1998), Cochrane Natl Cancer Inst 1993; 85 (18): 1499-1507. Paclitaxel solution contains a solvent, 7- Kudelka AP et al. “Phase II study of intravenous Cremophor EL°, that is incompatible with (1998, issue 1), Medidoc (1991-1994) and topotecan as a 5-day infusion for refractory epithe- Reactions (1983-June 1997), and the Minitel lial ovarian carcinoma” J Clin Oncol 1996; 14: the use of PVC infusion devices and war- version of the Pascal database up to 1552-1557. rants prior steroid administration because September 16 1997. SmithKline Beecham 8- Creemers GJ et al. “Topotecan, an active drug of its high sensitising potential (3). This is provided us with published and unpublished in the second-line treatment of epithelial ovarian documents, including the clinical expert cancer: results of a large European phase II study” not the case with topotecan. J Clin Oncol 1996; 14: 3056-3061. report. We also used the European public In all, 0.9% of patients died from 9- Ten Bokkel Huinink et al. “Topotecan versus assessment report (EPAR) available from the proven or probable toxicity on topote- paclitaxel for the treatment of recurrent epithelial European medicines agency. ovarian cancer” J Clin Oncol 1997; 15: 2183-2193. can, an incidence similar to that report- 10- European Agency for Medicinal Products ed with paclitaxel (9,11). And 5% of 1- NIH Consensus Development Panel on Ovarian (EMEA) “European public assessment report Cancer “Ovarian cancer - Screening, treatment (EPAR) Hycamtin” November 12, 1996: 32 pages. patients discontinued treatment with and follow-up” JAMA 1995; 273: 491-497. 11- Trimble EL et al. “Paclitaxel for platinum-refrac- topotecan because of severe adverse 2- Van Der Burg MEL et al. “The effect of debulk- tory ovarian cancer: results from the first 1 000 events (9). ing surgery after induction chemotherapy on the patients registered to National Cancer Institute prognosis in advanced epithelial ovarian cancer” Treatment Referral Center 9103” J Clin Oncol ©PI N Engl J Med 1995; 332: 629-634. 1993; 11: 2405-2410.
Translated from Rev Prescr Dec 1997; 17 (179): 807-809 benfluorex: what use? A SECOND LOOK POOR ASSESSMENT FILE
Abstract been done with morbidity or mortality contradictory. None of the three trials as end points. Available placebo-con- comparing benfluorex with a fibrate is ● The clinical file on the value of ben- trolled trials are small, methodologi- interpretable, because of fluorex for hypertriglyceridaemia is cally weak in most cases, and their methodological problems. highly inadequate. No clinical trials have results regarding triglyceride levels are
NOTHING There is no reason to prescribe benfluorex for hypertriglyceridaemia and diabetes. NEW
enfluorex (Biopharma, Servier most important question is the following: Tablets group), has been marketed in does benfluorex have proven • 150 mg per tablet B France since 1976, as tablets con- taining 150 mg (a). Chemically, benfluo- Biopharma a-In Europe, benfluorex is also marketed in Spain, rex is similar to other appetite suppres- Greece, Italy, Luxemburg, Portugal and ■ licensed indication in lipid disor- sants (b)(1). In France benfluorex has Switzerland (1). Benfluorex is not marketed in ders two approved indications. We recently English-speaking countries or Northern Europe. b- In France benfluorex has a peculiar classifica- “Adjunct to appropriate dietary mea- took another look at the file on the indi- tion. It is not officially classified among the appetite sures in hypertriglyceridaemia. The cation worded “adjunct to dietary mea- suppressants, meaning that its prescription is not restricted. However, the authorities decided on dietary measures must be continued. sures in asymptomatic overweight dia- October 25, 1995 (Journal Officiel, October 31, NB. There is no proven efficacy in pri- betic patients”, and concluded that its 1995: 15 937) to place benfluorex on a list of sub- mary or secondary prevention of com- stances that must not be used in freshly prepared slight effects on surrogate end points in mixtures, a list composed only of appetite sup- plications of atherosclerosis.” no way warranted prescription to diabetic pressants. Furthermore, the suffix -orex is attrib- uted to international nonproprietary names of lipid-lowering drug? patients (2). appetite suppressants by the World Health The second approved indication for Organisation (WHO) (1), and benfluorex is on the list of doping substances, together with amphetamines benfluorex is in the treatment of hyper- and other stimulants (Dictionnaire Vidal, French triglyceridaemia (see inset opposite). The data sheet compendium, 1997 edition, page 6).
P RESCRIRE I NTERNATIONAL A PRIL 1998/VOLUME 7 N° 34 • 49 Downloaded from english.prescrire.org on 28/09/2021 Copyright(c)Prescrire. For personal use only. New products / benfluorex